TABLE 1.
Patient Baseline Demographics and Clinical Characteristics a
| Prematched | Postmatched | |||||
|---|---|---|---|---|---|---|
| Pazopanib | Sunitinib | P Value | Pazopanib | Sunitinib | P Value | |
| (N = 97) | (N = 349) | (N = 84) | (N = 84) | |||
| Age, mean (SD [median]) | 62.3 (9.0 [62.0]) | 62.4 (9.9 [62.0]) | 0.957 | 63.9 (8.9 [63.0]) | 63.4 (9.0 [61.5]) | 0.592 |
| Male, n (%) | 75 (77.3) | 242 (69.3) | 0.125 | 64 (76.2) | 66 (78.6) | 0.727 |
| Insurance type, n (%) | ||||||
| Commercial | 71 (73.2) | 272 (77.9) | 0.327 | 62 (73.8) | 62 (73.8) | 1.000 |
| Medicare Advantage | 26 (26.8) | 77 (22.1) | 0.327 | 22 (26.2) | 22 (26.2) | 1.000 |
| Geographic region, n (%) | ||||||
| Northeast | 21 (21.7) | 80 (22.9) | 0.891 | 19 (22.6) | 16 (19.1) | 0.508 |
| Midwest | 23 (23.7) | 97 (27.8) | 0.518 | 19 (23.6) | 20 (23.8) | 1.000 |
| South | 40 (41.2) | 123 (35.2) | 0.286 | 35 (41.7) | 37 (44.1) | 0.688 |
| West | 13 (13.4) | 46 (13.2) | 1.000 | 11 (13.1) | 9 (10.7) | 0.688 |
| Other | 0 (0.0) | 3 (0.9) | 1.000 | 0 (0.0) | 2 (2.4) | - |
| Index year, n (%) | ||||||
| October-December 2009b,c | 3 (3.1) | 55 (15.8) | 0.001 | 3 (3.6) | 12 (14.3) | 0.035 |
| January-December 2010 | 36 (37.1) | 116 (33.2) | 0.476 | 34 (40.5) | 28 (33.3) | 0.238 |
| January-December 2011 | 31 (32.0) | 115 (33.0) | 0.854 | 28 (33.3) | 26 (31.0) | 0.688 |
| January-June 2012b | 27 (27.8) | 63 (18.1) | 0.034 | 19 (22.6) | 18 (21.4) | 1.000 |
| Selected comorbidities, n (%) | ||||||
| Hypertension | 49 (50.5) | 181 (51.9) | 0.814 | 44 (52.4) | 38 (45.2) | 0.396 |
| Horseshoe kidney | 0 (0.0) | 2 (0.6) | 1.000 | 0 (0.0) | 1 (1.2) | - |
| Polycystic kidney disease | 2 (2.1) | 6 (1.7) | 0.687 | 1 (1.2) | 1 (1.2) | 1.000 |
| Von Hippel-Lindau disease | 0 (0.0) | 0 (0.0) | - | 0 (0.0) | 0 (0.0) | - |
| Any radiation therapy, n (%) b | 9 (9.3) | 62 (17.8) | 0.043 | 9 (10.7) | 15 (17.9) | 0.146 |
| RCC-related surgery, n (%) b, c | 13 (13.0) | 50 (14.0) | 0.817 | 10 (11.9) | 6 (7.1) | 0.125 |
| Baseline Quan-Charlson comorbidity score, mean (SD [median]) | 5.79 (1.91 [6.00]) | 5.86 (2.08 [6.00]) | 0.770 | 5.81 (1.82 [6.00]) | 6.12 (1.83 [6.00]) | 0.133 |
a For the prematched population, we used Pearson’s chi-square to test differences in categorical data and the t-test for continuous data. If cell sizes were below 5, we used Fisher’s exact test for categorical data testing. For the matched population, we used the McNemar test to test differences in categorical data and the paired t-test for continuous data. If discordant pairs were < 20, we used the exact McNemar test for categorical data testing.
b P < 0.05 for comparison between prematched pazopanib vs. sunitinib.
c P< 0.05 for comparison between postmatched pazopanib vs. sunitinib.
RCC = renal cell carcinoma; SD = standard deviation.